Skip to main content

MicroHealth's OPAIS Wins 2022 Bronze Stevie

Team Will Be Celebrated During Event in London on 15 October



VIENNA, Va. - August 25, 2022 - (Newswire.com)

MicroHealth LLC, a leading Health Information Technology company, announced today that it has been awarded a Bronze Stevie Award for their Office of Pharmacy Affairs 340B Drug Pricing Program Information System (OPAIS). OPAIS consolidates steep discounts to assist low-income patients. Through 340B, 714 drug manufacturers provide their lowest bulk sales prices on 40,000+ medications to more than 47,000 hospitals and other healthcare providers.  

The International Business Awards are the world's premier business awards program, receiving entries from organizations in 67 nations and territories. Stevie Award winners were determined by the average scores of more than 300 executives worldwide who participated in the judging process. OPAIS was awarded a Bronze Stevie Award for Product Management Team of the Year.  

"One of the reasons [MicroHealth] has been effective at producing results and value to OPAIS is because of the trust, partnership and collaboration with the OPA team," said Chandra Ramanan, Deputy Program Manager.  
 

Boilerplate 

MicroHealth LLC is a leading Health Information Technology company that uses innovative technology and expertise from healthcare professionals to modernize health care IT for both Federal and commercial customers. As a Service-Disabled Veteran Owned (SDVOSB) (CVE-Verified) and an SBA Certified 8(a) small business, MicroHealth LLC employs more than 260 people across the nation. Visit www.microhealthllc.com to learn more, or click here to view MicroHealth's full capabilities statement. 

Media Contact:   

Andrew Tran  

301.873.7598  

andrew.tran@microhealthllc.com  




Press Release Service by Newswire.com

Original Source: MicroHealth's OPAIS Wins 2022 Bronze Stevie
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.